ProCE Banner Activity

BCMA Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access

Events

BCMA Immunotherapy, Bispecific Platforms, and CD38 Antibodies in Myeloma: Optimizing Treatment & Enhancing Access

Released: May 13, 2024

Expiration: May 12, 2025

Share

Supporters

Supported by an educational grant from Sanofi Genzyme.

Sanofi Genzyme